August 11th 2025
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.
Managing Treatment-Resistant Depression: Tips for the Outpatient Psychiatrist
March 20th 2024Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.
Read More
Augmentation Strategies for Treatment-Resistant Depression
March 19th 2024Given that two-thirds of patients treated for a major depressive episode will fail to achieve remission of symptoms after 2 or more treatment trials of first-line antidepressants, the probability of remission will further decrease with subsequent medication trials. Treatment strategies for patients with TRD include augmentation, where a medication is added to a current antidepressant versus switching to a different antidepressant.
Read More
Exploring the STAR*D Controversy
March 5th 2024STAR*D trial is one of the most important foundational studies in psychiatry to guide the treatment of unipolar major depression. Get ready to explore a dialogue between the original STAR*D authors and a group of authors who call STAR*D into question.
Read More